Abstract 1826: Exposure-response analysis and quantitative systems pharmacology modeling for an optimal dose selection of surovatamig in patients with DLBCL.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institutions: AstraZeneca (United States), AstraZeneca (United Kingdom)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148808105
Cites:
Cited by:
Related to: